XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
GOODWILL AND OTHER INTANGIBLES (Tables)
 9 Months Ended
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of changes in the carrying amount of goodwill
The following table presents information about our goodwill at September 30, 2021 and December 31, 2020 (in thousands):
Branded PharmaceuticalsSterile InjectablesGeneric PharmaceuticalsInternational PharmaceuticalsTotal
Goodwill as of December 31, 2020$828,818 $2,731,193 $— $— $3,560,011 
Goodwill as of September 30, 2021$828,818 $2,731,193 $— $— $3,560,011 
The carrying amounts of goodwill at September 30, 2021 and December 31, 2020 are net of the following accumulated impairments (in thousands):
Branded PharmaceuticalsSterile InjectablesGeneric PharmaceuticalsInternational PharmaceuticalsTotal
Accumulated impairment losses as of December 31, 2020$855,810 $— $3,142,657 $546,251 $4,544,718 
Accumulated impairment losses as of September 30, 2021$855,810 $— $3,142,657 $548,477 $4,546,944 
Schedule of other intangible assets
Changes in the amounts of other intangible assets for the nine months ended September 30, 2021 are set forth in the table below (in thousands). This table excludes changes related to assets classified as held for sale to the extent such changes occurred after the assets were classified as held for sale.
Cost basis:Balance as of December 31, 2020AcquisitionsImpairmentsOther (1)Effect of Currency TranslationBalance as of September 30, 2021
Indefinite-lived intangibles:
In-process research and development$3,000 $— $— $(3,000)$— $— 
Total indefinite-lived intangibles$3,000 $— $— $(3,000)$— $— 
Finite-lived intangibles:
Licenses (weighted average life of 14 years)
$439,230 $4,177 $(1,300)$— $— $442,107 
Tradenames6,409 — — — — 6,409 
Developed technology (weighted average life of 12 years)
6,442,734 — (6,511)(210,476)1,063 6,226,810 
Total finite-lived intangibles (weighted average life of 12 years)
$6,888,373 $4,177 $(7,811)$(210,476)$1,063 $6,675,326 
Total other intangibles$6,891,373 $4,177 $(7,811)$(213,476)$1,063 $6,675,326 
Accumulated amortization:Balance as of December 31, 2020AmortizationImpairmentsOther (1)Effect of Currency TranslationBalance as of September 30, 2021
Finite-lived intangibles:
Licenses$(415,193)$(3,595)$— $— $— $(418,788)
Tradenames(6,409)— — — — (6,409)
Developed technology(3,728,963)(277,506)— 211,196 (501)(3,795,774)
Total other intangibles$(4,150,565)$(281,101)$— $211,196 $(501)$(4,220,971)
Net other intangibles$2,740,808 $2,454,355 
__________
(1)Includes reclassification adjustments of $3.0 million for certain developed technology intangible assets, previously classified as in-process research and development, that were placed in service during the nine months ended September 30, 2021, as well as the transfer of certain developed technology intangible assets with a cost basis of $213.5 million and accumulated amortization of $211.2 million to Assets held for sale, as further discussed in Note 3. Discontinued Operations and Held for Sale.
Schedule of future amortization expense For intangible assets subject to amortization, estimated amortization expense for the five fiscal years subsequent to December 31, 2020 is as follows (in thousands):
2021$372,900 
2022$357,054 
2023$314,904 
2024$280,280 
2025$258,621 
Schedule of intangible asset impairment charges including goodwill
During the three and nine months ended September 30, 2021 and 2020, the Company incurred the following goodwill and other intangible asset impairment charges (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Goodwill impairment charges$— $— $— $32,786 
Other intangible asset impairment charges$— $2,020 $7,811 $65,771